Becton Dickinson and Co (BDX) was Reiterated by RBC Capital Mkts to “Sector Perform” according to the research note released today. The brokerage firm has raised the Price Target to $ 169 from a previous price target of $153 . RBC Capital Mkts advised their investors in a research report released on May 9, 2016.
Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Upgraded by Deutsche Bank on Feb 11, 2016 to ” Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $155 .
On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.
Becton Dickinson and Co closed down -0.37 points or -0.22% at $164.84 with 15,45,913 shares getting traded on Friday. Post opening the session at $163, the shares hit an intraday low of $162.47 and an intraday high of $165 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Dec 14, 2015, Stephen Sichak (Executive Vice President) sold 8,670 shares at $152.21 per share price. According to the SEC, on Dec 9, 2015, William A Kozy (Executive Vice President) sold 15,495 shares at $154.43 per share price. On Dec 8, 2015, Vincent A Forlenza (Chairman, CEO and President) sold 17,762 shares at $153.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.